Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Experimental Hematology & Oncology
Published in: Experimental Hematology & Oncology 1/2013

Open Access 01-12-2013 | Short report

Evaluation of serum Amphiregulin levels in breast cancer patients and cancer-free controls

Authors: Esther A Peterson, Eirini Pectasides, Shabana Shabbeer, Lisa Wiechmann, Joseph A Sparano, Paraic A Kenny

Published in: Experimental Hematology & Oncology | Issue 1/2013

Login to get access

Abstract

Background

Expression of the Epidermal Growth Factor Receptor ligand, Amphiregulin, has been associated with estrogen receptor positive breast cancer. As Amphiregulin is proteolytically released from the surface of breast cancer cells, we investigated the levels of Amphiregulin in the serum of breast cancer patients and cancer-free women to evaluate its potential utility as a breast cancer biomarker.

Findings

Serum Amphiregulin levels were quantified by ELISA from 125 cancer-free women and 114 breast cancer patients. No significant association between serum Amphiregulin levels and breast cancer status was detected at two cut-points evaluated.

Conclusions

Measurement of serum Amphiregulin levels lacks the necessary sensitivity and specificity for breast cancer screening in the general population.
Appendix
Available only for authorised users
Literature
1.
Shoyab M, McDonald VL, Bradley JG, Todaro GJ: Amphiregulin: a bifunctional growth-modulating glycoprotein produced by the phorbol 12-myristate 13-acetate-treated human breast adenocarcinoma cell line MCF-7. Proc Natl Acad Sci USA 1988, 85: 6528–6532. 10.1073/pnas.85.17.6528PubMedCentralPubMedCrossRef
2.
Martinez-Lacaci I, Saceda M, Plowman GD, Johnson GR, Normanno N, Salomon DS, Dickson RB: Estrogen and phorbol esters regulate amphiregulin expression by two separate mechanisms in human breast cancer cell lines. Endocrinology 1995, 136: 3983–3992. 10.1210/en.136.9.3983PubMed
3.
4.
Kenny PA: Tackling EGFR signaling with TACE antagonists: a rational target for metalloprotease inhibitors in cancer. Expert Opin Ther Targets 2007, 11: 1287–1298. 10.1517/14728222.11.10.1287PubMedCrossRef
5.
Meany DL, Sokoll LJ, Chan DW: Early detection of cancer: immunoassays for plasma tumor markers. Expert Opin Med Diagn 2009, 3: 597–605. 10.1517/17530050903266830PubMedCentralPubMedCrossRef
6.
Peterson EA, Shabbeer S, Kenny PA: Normal range of serum Amphiregulin in healthy adult human females. Clin Biochem 2012, 45: 460–463. 10.1016/j.clinbiochem.2011.12.029PubMedCrossRef
Metadata
Title
Evaluation of serum Amphiregulin levels in breast cancer patients and cancer-free controls
Authors
Esther A Peterson
Eirini Pectasides
Shabana Shabbeer
Lisa Wiechmann
Joseph A Sparano
Paraic A Kenny
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Experimental Hematology & Oncology / Issue 1/2013
Electronic ISSN: 2162-3619
DOI
https://doi.org/10.1186/2162-3619-2-25

Other articles of this Issue 1/2013

Experimental Hematology & Oncology 1/2013 Go to the issue

Research

A standardized microarray assay for the independent gene expression markers in AML: EVI1 and BAALC

Review

Metaplastic breast cancer: histologic characteristics, prognostic factors and systemic treatment strategies

Research

Overcoming bortezomib resistance in human B cells by anti-CD20/rituximab-mediated complement-dependent cytotoxicity and epoxyketone-based irreversible proteasome inhibitors

Research

Opticin, a small leucine-rich proteoglycan, is uniquely expressed and translocated to the nucleus of chronic lymphocytic leukemia cells

Research

Inhibition of transketolase by oxythiamine altered dynamics of protein signals in pancreatic cancer cells

Research

The relative efficacy of imatinib, dasatinib and nilotinib for newly diagnosed chronic myeloid leukemia: a systematic review and network meta-analysis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits